H
Hui Zhou
Publications - 3
Citations - 364
Hui Zhou is an academic researcher. The author has contributed to research in topics: Bevacizumab & Hepatocellular carcinoma. The author has an hindex of 2, co-authored 3 publications receiving 24 citations.
Papers
More filters
Journal ArticleDOI
Sintilimab plus a bevacizumab biosimilar (IBI305) versus sorafenib in unresectable hepatocellular carcinoma (ORIENT-32): a randomised, open-label, phase 2-3 study.
Zhenggang Ren,Jianming Xu,Yuxian Bai,Aibing Xu,Shundong Cang,Chengyou Du,Qiu Li,Yinying Lu,Yajin Chen,Yabing Guo,Zhendong Chen,Baorui Liu,Weidong Jia,Jian Wu,Junye Wang,Guoliang Shao,Bixiang Zhang,Yunfeng Shan,Zhiqiang Meng,Jianbing Wu,Shanzhi Gu,Wei Yang,Chao Liu,Xuetao Shi,Zhenyuan Gao,Tao Yin,Jiuwei Cui,Ming Huang,Baocai Xing,Yilei Mao,Gao-Jun Teng,Yanru Qin,Jinhai Wang,Feng Xia,Guowen Yin,Yong Yang,Mingxia Chen,Yan Wang,Hui Zhou,Jia Fan +39 more
TL;DR: The phase 2-3 ORIENT-32 study as discussed by the authors compared sintilimab (a PD-1 inhibitor) plus IBI305, a bevacizumab biosimilar, versus sorafenib as a first-line treatment for unresectable HBV-associated hepatocellular carcinoma.
Journal ArticleDOI
Preliminary results of sintilimab plus different dose of IBI305 (anti-VEGF monoclonal antibody) in patients with advanced hepatocellular carcinoma: A phase Ib study.
Wen Zhang,Xinyu Bi,Yongkun Sun,Yue Yu,Jianguo Zhou,Huiying Zeng,Fan Wu,Yang Luo,Yong Yang,Mingxia Chen,Yan Wang,Hui Zhou,Jianqiang Cai,Hong Zhao,Aiping Zhou +14 more
TL;DR: This study aimed to evaluate the safety and efficacy of sintilimab, a PD-1 blockade, plus IBI305, a biosimilar candidate of bevacizumab, in patients with advanced hepatocellula...
Journal ArticleDOI
Preliminary results of a phase 1b study of fruquintinib plus sintilimab in advanced colorectal cancer.
Ye Guo,Weijie Zhang,Jieer Ying,Yanqiao Zhang,Yueyin Pan,Wensheng Qiu,Weiguo Su,Panfeng Tan,Hongyan Yin,Yan Wang,Yang Luo,Hui Zhou,Jin Li +12 more
TL;DR: Fruquintinib plus sintilimab showed promising efficacy and favorable safety profile in advanced CRC and other solid tumors, and the primary endpoints were safety and tolerability and secondary endpoint was objective response rate (ORR).